Literature DB >> 8175032

Infections in chronic lymphocytic leukemia. Analysis of incidence as a function of length of follow-up.

S Molica1, D Levato, L Levato.   

Abstract

BACKGROUND AND METHODS: Infections represent the major cause of death in chronic lymphocytic leukemia (CLL); however, clinical studies dealing with their incidence have yielded inconclusive results. In order to address this issue we reviewed the records of 125 CLL patients (mean age 65.6 yrs; 81 M/44 F; Stage A, 48; Stage B, 37; Stage C, 40) followed up at our institution over a 10-year period.
RESULTS: The 125 patients accrued 447 person-years, a mean of 3.8 years per person. There were 199 recorded infections: 47 severe (crude rate 9.8 per 100 person-years) and 72 moderate, respectively. The 5-year risk of developing a severe infection for the whole series was 26% (95% CI: 24.7-27.3%), and 21 out of 71 deaths (29.5%) could be attributed to infectious causes. Despite a linear trend toward increased risk (r = 0.98), hazard function analysis showed a constant pattern of risk (r = 0.30), suggesting a lack of correlation of this event with time. Furthermore, the 5-year risk of developing a severe infection increased to 57.1% (95% CI: 36.4-77.8%) for patients with low IgG levels (less than 6.5 gr/L), and to 68% for those with both low IgG levels and disease stage C. On the other hand, patients who experienced a severe infection more frequently had advanced clinical stage (P < 0.001), low IgG levels (P < 0.01) and diffuse bone marrow (BM) histology (P < 0.05).
CONCLUSIONS: Infection is a constant risk in CLL that is associated with shortened survival. Factors such as hypogammaglobulinemia and advanced disease appear to be the major predisposing factors.

Entities:  

Mesh:

Year:  1993        PMID: 8175032

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  13 in total

1.  Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.

Authors:  Steven E Coutre; John C Byrd; Peter Hillmen; Jacqueline C Barrientos; Paul M Barr; Stephen Devereux; Tadeusz Robak; Thomas J Kipps; Anna Schuh; Carol Moreno; Richard R Furman; Jan A Burger; Michael O'Dwyer; Paolo Ghia; Rudolph Valentino; Stephen Chang; James P Dean; Danelle F James; Susan M O'Brien
Journal:  Blood Adv       Date:  2019-06-25

2.  Outcomes in critically ill chronic lymphocytic leukemia patients.

Authors:  Aliénor Xhaard; Loic Epelboin; David Schnell; François Vincent; Vincent Levy; Marion Malphettes; Elie Azoulay; Michaël Darmon
Journal:  Support Care Cancer       Date:  2013-02-15       Impact factor: 3.603

3.  Free light chains and the risk of AIDS-defining opportunistic infections in HIV-infected individuals.

Authors:  Meredith S Shiels; Ola Landgren; Rene Costello; Adriana Zingone; James J Goedert; Eric A Engels
Journal:  Clin Infect Dis       Date:  2012-08-14       Impact factor: 9.079

Review 4.  A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia.

Authors:  S Lachance; A L Christofides; J K Lee; L H Sehn; B C Ritchie; C Shustik; D A Stewart; C L Toze; E Haddad; D C Vinh
Journal:  Curr Oncol       Date:  2016-02-18       Impact factor: 3.677

5.  Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia.

Authors:  C Steininger; L Z Rassenti; K Vanura; K Eigenberger; U Jäger; T J Kipps; C Mannhalter; S Stilgenbauer; T Popow-Kraupp
Journal:  Eur J Clin Invest       Date:  2009-06       Impact factor: 4.686

Review 6.  Immunologic monitoring in chronic lymphocytic leukemia.

Authors:  William G Wierda
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

7.  Serum globulins as marker of immune restoration after treatment with high-dose rituximab for chronic lymphocytic leukemia.

Authors:  Doru T Alexandrescu; Peter H Wiernik
Journal:  Med Oncol       Date:  2008-01-05       Impact factor: 3.064

8.  Genetic polymorphisms, chronic lymphocytic leukemia, and the future: are we there yet?

Authors:  Paolo F Caimi; Marcos de Lima
Journal:  Rev Bras Hematol Hemoter       Date:  2014

9.  Chronic lymphocytic leukemia patients have a preserved cytomegalovirus-specific antibody response despite progressive hypogammaglobulinemia.

Authors:  Katrina Vanura; Franz Rieder; Marie-Theres Kastner; Julia Biebl; Michael Sandhofer; Trang Le; Robert Strassl; Elisabeth Puchhammer-Stöckl; Thomas Perkmann; Christoph F Steininger; Kostas Stamatopoulos; Wolfgang Graninger; Ulrich Jäger; Christoph Steininger
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

Review 10.  Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?

Authors:  Clare Sun; Adrian Wiestner
Journal:  Hematol Oncol Clin North Am       Date:  2021-05-26       Impact factor: 2.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.